SNODGRASS H. RALPH (PRES./CHIEF SCIENTIFIC OFFICER) purchased 12.1% of their position (3.75K shares) of VISTAGEN THERAPEUTICS, INC. on the open market
Open‑market purchase worth $10.2K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 8/18/2021ACC: 0001415889-21-004002
DirectorOfficer· PRES./CHIEF SCIENTIFIC OFFICER
Since Aug 2018
+3.75K
Net shares
Net buyer
$10.2K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
3.75K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+3.75K
Price / share
$2.73
Trade value
$10.24K
% of position
12.1%
8/17/2021
30.89K→34.64K
Total
Net shares
+3.75K
Net value
$10.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/17/2021 | P · Purchase | +3.75K | $2.73 | $10.24K | 12.1% | 30.89K | 34.64K |
| Total | +3.75K | $10.24K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned60.22K
Total
60.22K direct60.22K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 60.22K | Direct |
| Total | 60.22K | 60.22K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported